Glucagon News and Research

RSS

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), a more aggressive form of the condition that normally responds less well to treatment, as it is at treating T2D diagnosed later in life, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has found.

4 Oct 2023

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

25 Sep 2023

Could metformin be a game changer for heart health in non-diabetics?

Using Mendelian randomization, researchers found that altering seven metformin targets led to improved blood pressure and BMI in non-diabetic individuals. The study suggests the potential for metformin's role in reducing cardiovascular risks in the general population, although more research is needed.

24 Sep 2023

Research reveals racial and ethnic disparities in the benefits of newer type 2 diabetes drugs

New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.

21 Sep 2023

Ketogenic dietary intervention may inhibit onset and progression of neuroendocrine tumors

A recent Cell Death and Disease study evaluated the effect of ketogenic dietary intervention on neuroendocrine tumors.

12 Sep 2023

Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complications

The study used a genome-wide association study (GWAS) to analyze random glucose levels in nearly half a million non-diabetic subjects, uncovering 150 distinct genetic signals, including 53 new ones, linked to glycemic traits and type 2 diabetes. The research also discovered a causal effect of random glucose and type 2 diabetes on lung function, identifying lung dysfunction as a new diabetes complication.

10 Sep 2023

Theabrownin from dark tea may have the potential to treat insulin resistance

The effects of theabrownin (TB) from dark tea treatment on insulin resistance (IR).

8 Sep 2023

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice. The findings suggest that this drug could be a promising treatment for obesity and offer a suitable animal model for future research.

3 Sep 2023

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction.

31 Aug 2023

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children's health.

28 Aug 2023

UAB researchers show beneficial effect of verapamil for patients with Type 1 diabetes

In 2012, University of Alabama at Birmingham researcher Anath Shalev, M.D., reported that a decades-old blood pressure medication called verapamil completely reversed diabetes in animal models.

25 Aug 2023

Semaglutide could be a game-changer for patients with HFpEF and obesity

Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

25 Aug 2023

Ketogenic diets, gut microbiota, and health effects

The evidence on ketogenic diets (KDs) from the past three decades.

24 Aug 2023

$9.57 million grant will support a clinical trial to study new treatment option for NAFLD

According to the National Institutes of Health, approximately 24% of adults in the United States have nonalcoholic fatty liver disease (NAFLD), an umbrella term for a range of liver conditions affecting people who drink little to no alcohol that can lead to cirrhosis, liver cancer and liver failure.

23 Aug 2023

Study explores mechanism behind liraglutide-associated weight loss in obese individuals

A new study suggests that liraglutide is associated with the normalization of associative learning in obese individuals with insulin resistance.

22 Aug 2023

How effective is the keto diet for managing PCOS?

Scientists discuss the metabolic advantages of the ketogenic diet in the management of polycystic ovarian syndrome.

21 Aug 2023

Study: 93 million U.S. adults may benefit from semaglutide medication

Researchers from the University of California, Irvine have just published a study that projects 93 million U.S. adults that are overweight and obese may be suitable for the 2.4 mg dosage of semaglutide, a weight loss medication known under the brand name Wegovy.

16 Aug 2023

Can fasting benefit individuals with diabetes?

Fasting and its effect on diabetes.

15 Aug 2023

Revolutionizing type 2 diabetes treatment: personalized approach shows promise in matching patients with optimal glucose-lowering therapies

A personalized therapy selection algorithm for two diabetes type 2 (T2D) treatment drug classes.

10 Aug 2023

Unlocking the potential of Reg3γ: new insights into its metabolic functions and therapeutic prospects

Researchers evaluated the physiological roles of an antimicrobial peptide.

3 Aug 2023